Teresa P. DiLorenzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Teresa P. DiLorenzo has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer Schloss
Memorial Sloan Kettering Cancer Center 1 Head and Neck Service, Department of Surgery New York, New York
6 shared publications Gayatri Mukherjee
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA
5 shared publicationsJeffrey Babad
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA
5 shared publications- Riyasat Ali
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India
5 shared publications Alessandro Sette
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology , La Jolla, CA
3 shared publicationsCarla Smith
Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, NY
3 shared publications
Latest Publications
- 9 February 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (2)
Identification of immunodominant T cell epitopes in SARS-CoV-2 spike protein in Syrian hamsters
T cell immunity has a crucial role in vaccine-induced protection against respiratory viruses, yet a detailed characterization of T cell responses and epitopes in Syrian hamsters, a highly utilized preclinical, small animal model for SARS-CoV-2 research, is lacking. In this study, using an intranasal Chimpanzee adenoviral vectored vaccine (ChAd-SARS-CoV-2-S), we characterized the T cell response to the spike protein of SARS-CoV-2 in Syrian hamsters and identified immunogenic CD4+ and CD8+ T cell epitopes using IFN-γ ELISpot assays and cell depletions. The mucosal ChAd-SARS-CoV-2-S vaccine elicited strong T cell responses, with evidence of CD4+ and CD8+ T cell activation in both lymphoid and mucosal tissues. Responses were directed toward the non–receptor-binding domain regions of the spike protein, indicating that dominant T cell epitopes for hamsters reside elsewhere in this structural protein. Six different T cell epitopes (4 for CD4 and 2 for CD8) were identified in the spike protein, and epitope-specific responses were detected in hamsters from 2 vendors, suggesting genetic similarity in terms of major histocompatibility complex allele expression. Identifying T cell epitopes and characterizing T cell responses in lymphoid and mucosal compartments enhances the utility of Syrian hamsters as a preclinical model for SARS-CoV-2 vaccine studies.
- 9 February 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (2)
Identification of immunodominant T cell epitopes in SARS-CoV-2 spike protein in Syrian hamsters
T cell immunity has a crucial role in vaccine-induced protection against respiratory viruses, yet a detailed characterization of T cell responses and epitopes in Syrian hamsters, a highly utilized preclinical, small animal model for SARS-CoV-2 research, is lacking. In this study, using an intranasal Chimpanzee adenoviral vectored vaccine (ChAd-SARS-CoV-2-S), we characterized the T cell response to the spike protein of SARS-CoV-2 in Syrian hamsters and identified immunogenic CD4+ and CD8+ T cell epitopes using IFN-γ ELISpot assays and cell depletions. The mucosal ChAd-SARS-CoV-2-S vaccine elicited strong T cell responses, with evidence of CD4+ and CD8+ T cell activation in both lymphoid and mucosal tissues. Responses were directed toward the non–receptor-binding domain regions of the spike protein, indicating that dominant T cell epitopes for hamsters reside elsewhere in this structural protein. Six different T cell epitopes (4 for CD4 and 2 for CD8) were identified in the spike protein, and epitope-specific responses were detected in hamsters from 2 vendors, suggesting genetic similarity in terms of major histocompatibility complex allele expression. Identifying T cell epitopes and characterizing T cell responses in lymphoid and mucosal compartments enhances the utility of Syrian hamsters as a preclinical model for SARS-CoV-2 vaccine studies.
- 9 February 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (2)
Islet-derived T cells from both mice and humans recognize conserved insulin A-chain peptides presented by HLA-C*03:04
Type 1 diabetes (T1D) is an autoimmune disease in which T cells mediate the elimination of the insulin-producing beta cells in the pancreatic islets, resulting in the need for exogenous insulin. Studies of T1D in both patients and the nonobese diabetic (NOD) mouse model of the disease illustrate that beta cell–specific CD8+ T cells are central contributors to the beta cell destruction characterizing the disease. Compared to HLA-A and HLA-B, relatively little is known about the participation of HLA-C–restricted T cells in T1D. To tackle this question, we developed and characterized an NOD-based model of spontaneous T1D that transgenically expresses HLA-C*03:04, a common and enriched allotype in T1D patients. Using an unbiased screen of an exhaustive peptide library comprised of 8- to 11-mer peptides derived from the key autoantigen insulin, islet-infiltrating T cells from the mice were found to recognize the insulin A-chain peptides A11-19 and A13-21 presented by HLA-C*03:04. Guided by these findings, T-cell lines were established from the islets of HLA-C*03:04-positive human donors with T1D, including a donor with demise at onset of T1D. These human islet-derived T cells also responded to the conserved A11-19 and A13-21 peptides. The presence of HLA-C*03:04-restricted insulin-specific T cells in both mouse and human islets suggests the participation of peptides presented by HLA-C molecules in T1D pathogenesis. This work also demonstrates the utility of the mouse model in identifying human disease–relevant HLA-C–restricted epitopes and suggests a general strategy for the exploration and manipulation of HLA-C–restricted T cells in autoimmune diseases.
- 9 February 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (2)
Islet-derived T cells from both mice and humans recognize conserved insulin A-chain peptides presented by HLA-C*03:04
Type 1 diabetes (T1D) is an autoimmune disease in which T cells mediate the elimination of the insulin-producing beta cells in the pancreatic islets, resulting in the need for exogenous insulin. Studies of T1D in both patients and the nonobese diabetic (NOD) mouse model of the disease illustrate that beta cell–specific CD8+ T cells are central contributors to the beta cell destruction characterizing the disease. Compared to HLA-A and HLA-B, relatively little is known about the participation of HLA-C–restricted T cells in T1D. To tackle this question, we developed and characterized an NOD-based model of spontaneous T1D that transgenically expresses HLA-C*03:04, a common and enriched allotype in T1D patients. Using an unbiased screen of an exhaustive peptide library comprised of 8- to 11-mer peptides derived from the key autoantigen insulin, islet-infiltrating T cells from the mice were found to recognize the insulin A-chain peptides A11-19 and A13-21 presented by HLA-C*03:04. Guided by these findings, T-cell lines were established from the islets of HLA-C*03:04-positive human donors with T1D, including a donor with demise at onset of T1D. These human islet-derived T cells also responded to the conserved A11-19 and A13-21 peptides. The presence of HLA-C*03:04-restricted insulin-specific T cells in both mouse and human islets suggests the participation of peptides presented by HLA-C molecules in T1D pathogenesis. This work also demonstrates the utility of the mouse model in identifying human disease–relevant HLA-C–restricted epitopes and suggests a general strategy for the exploration and manipulation of HLA-C–restricted T cells in autoimmune diseases.
- Open Access
- 22 August 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (9) , 107702
Structural and biochemical analysis of highly similar HLA-B allotypes differentially associated with type 1 diabetes
- 22 August 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (9) , 107702
Open AccessStructural and biochemical analysis of highly similar HLA-B allotypes differentially associated with type 1 diabetes
- 22 May 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (9) , 2350949
Human insulin as both antigen and protector in type 1 diabetes
Type 1 diabetes (T1D) is characterized by T‐cell responses to islet antigens. Investigations in humans and the nonobese diabetic (NOD) mouse model of T1D have revealed that T‐cell reactivity to insulin plays a central role in the autoimmune response. As there is no convenient NOD‐based model to study human insulin (hIns) or its T‐cell epitopes in the context of spontaneous T1D, we developed a NOD mouse strain transgenically expressing hIns in islets under the control of the human regulatory region. Female NOD.hIns mice developed T1D at approximately the same rate and overall incidence as NOD mice. Islet‐infiltrating T cells from NOD.hIns mice recognized hIns peptides; both CD8 and CD4 T‐cell epitopes were identified. We also demonstrate that islet‐infiltrating T cells from HLA‐transgenic NOD.hIns mice can be used to identify potentially patient‐relevant hIns T‐cell epitopes. Besides serving as an antigen, hIns was expressed in the thymus of NOD.hIns mice and could serve as a protector against T1D under certain circumstances, as previously suggested by genetic studies in humans. NOD.hIns mice and related strains facilitate human‐relevant epitope discovery efforts and the investigation of fundamental questions that cannot be readily addressed in humans.
- 22 May 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (9) , 2350949
Human insulin as both antigen and protector in type 1 diabetes
Type 1 diabetes (T1D) is characterized by T‐cell responses to islet antigens. Investigations in humans and the nonobese diabetic (NOD) mouse model of T1D have revealed that T‐cell reactivity to insulin plays a central role in the autoimmune response. As there is no convenient NOD‐based model to study human insulin (hIns) or its T‐cell epitopes in the context of spontaneous T1D, we developed a NOD mouse strain transgenically expressing hIns in islets under the control of the human regulatory region. Female NOD.hIns mice developed T1D at approximately the same rate and overall incidence as NOD mice. Islet‐infiltrating T cells from NOD.hIns mice recognized hIns peptides; both CD8 and CD4 T‐cell epitopes were identified. We also demonstrate that islet‐infiltrating T cells from HLA‐transgenic NOD.hIns mice can be used to identify potentially patient‐relevant hIns T‐cell epitopes. Besides serving as an antigen, hIns was expressed in the thymus of NOD.hIns mice and could serve as a protector against T1D under certain circumstances, as previously suggested by genetic studies in humans. NOD.hIns mice and related strains facilitate human‐relevant epitope discovery efforts and the investigation of fundamental questions that cannot be readily addressed in humans.
- Open Access
- 1 July 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (1) , 100827
Noncontiguous T cell epitopes in autoimmune diabetes: From mice to men and back again
- 1 July 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (1) , 100827
Open AccessNoncontiguous T cell epitopes in autoimmune diabetes: From mice to men and back again
- 15 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (7) , 1311-1335
T-Cell Epitopes and Neo-epitopes in Type 1 Diabetes: A Comprehensive Update and Reappraisal
The autoimmune disease type 1 diabetes is characterized by effector T-cell responses to pancreatic β-cell–derived peptides presented by HLA class I and class II molecules, leading ultimately to β-cell demise and insulin insufficiency. Although a given HLA molecule presents a vast array of peptides, only those recognized by T cells are designated as epitopes. Given their intimate link to etiology, the discovery and characterization of T-cell epitopes is a critical aspect of type 1 diabetes research. Understanding epitope recognition is also crucial for the pursuit of antigen-specific immunotherapies and implementation of strategies for T-cell monitoring. For these reasons, a cataloging and appraisal of the T-cell epitopes targeted in type 1 diabetes was completed over a decade ago, providing an important resource for both the research and the clinical communities. Here we present a much needed update and reappraisal of this earlier work and include online supplementary material where we cross-index each epitope with its primary references and Immune Epitope Database (IEDB) identifier. Our analysis includes a grading scale to score the degree of evidence available for each epitope, which conveys our perspective on several useful criteria for epitope evaluation. While providing an efficient summary of the arguably impressive current state of knowledge, this work also brings to light several deficiencies. These include the need for improved epitope validation, as few epitopes score highly by the criteria employed, and the dearth of investigations of the epitopes recognized in the context of several understudied type 1 diabetes–associated HLA molecules.
- 15 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (7) , 1311-1335
T-Cell Epitopes and Neo-epitopes in Type 1 Diabetes: A Comprehensive Update and Reappraisal
The autoimmune disease type 1 diabetes is characterized by effector T-cell responses to pancreatic β-cell–derived peptides presented by HLA class I and class II molecules, leading ultimately to β-cell demise and insulin insufficiency. Although a given HLA molecule presents a vast array of peptides, only those recognized by T cells are designated as epitopes. Given their intimate link to etiology, the discovery and characterization of T-cell epitopes is a critical aspect of type 1 diabetes research. Understanding epitope recognition is also crucial for the pursuit of antigen-specific immunotherapies and implementation of strategies for T-cell monitoring. For these reasons, a cataloging and appraisal of the T-cell epitopes targeted in type 1 diabetes was completed over a decade ago, providing an important resource for both the research and the clinical communities. Here we present a much needed update and reappraisal of this earlier work and include online supplementary material where we cross-index each epitope with its primary references and Immune Epitope Database (IEDB) identifier. Our analysis includes a grading scale to score the degree of evidence available for each epitope, which conveys our perspective on several useful criteria for epitope evaluation. While providing an efficient summary of the arguably impressive current state of knowledge, this work also brings to light several deficiencies. These include the need for improved epitope validation, as few epitopes score highly by the criteria employed, and the dearth of investigations of the epitopes recognized in the context of several understudied type 1 diabetes–associated HLA molecules.
- Open Access
- 1 June 2019
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 3 (6) , 236-253
Development and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes
Dendritic cells (DCs) are crucial for the production of adaptive immune responses to disease-causing microbes. However, in the steady state (i.e., in the absence of an infection or when Ags are experimentally delivered without a DC-activating adjuvant), DCs present Ags to T cells in a tolerogenic manner and are important for the establishment of peripheral tolerance. Delivery of islet Ags to DCs using Ag-linked Abs to the DC endocytic receptor CD205 has shown promise in the NOD mouse model of type 1 diabetes (T1D). It is important to note, however, that all myeloid DCs express CD205 in humans, whereas in mice, only one of the classical DC subsets does (classical DC1; CD8α+ in spleen). Thus, the evaluation of CD205-targeted treatments in mice will likely not accurately predict the results observed in humans. To overcome this challenge, we have developed and characterized a novel NOD mouse model in which all myeloid DCs transgenically express human CD205 (hCD205). This NOD.hCD205 strain displays a similar T1D incidence profile to standard NOD mice. The presence of the transgene does not alter DC development, phenotype, or function. Importantly, the DCs are able to process and present Ags delivered via hCD205. Because Ags taken up via hCD205 can be presented on both class I and class II MHC, both CD4+ and CD8+ T cells can be modulated. As both T cell subsets are important for T1D pathogenesis, NOD.hCD205 mice represent a unique, patient-relevant tool for the development and optimization of DC-directed T1D therapies.
- 1 June 2019
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 3 (6) , 236-253
Open AccessDevelopment and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes
Dendritic cells (DCs) are crucial for the production of adaptive immune responses to disease-causing microbes. However, in the steady state (i.e., in the absence of an infection or when Ags are experimentally delivered without a DC-activating adjuvant), DCs present Ags to T cells in a tolerogenic manner and are important for the establishment of peripheral tolerance. Delivery of islet Ags to DCs using Ag-linked Abs to the DC endocytic receptor CD205 has shown promise in the NOD mouse model of type 1 diabetes (T1D). It is important to note, however, that all myeloid DCs express CD205 in humans, whereas in mice, only one of the classical DC subsets does (classical DC1; CD8α+ in spleen). Thus, the evaluation of CD205-targeted treatments in mice will likely not accurately predict the results observed in humans. To overcome this challenge, we have developed and characterized a novel NOD mouse model in which all myeloid DCs transgenically express human CD205 (hCD205). This NOD.hCD205 strain displays a similar T1D incidence profile to standard NOD mice. The presence of the transgene does not alter DC development, phenotype, or function. Importantly, the DCs are able to process and present Ags delivered via hCD205. Because Ags taken up via hCD205 can be presented on both class I and class II MHC, both CD4+ and CD8+ T cells can be modulated. As both T cell subsets are important for T1D pathogenesis, NOD.hCD205 mice represent a unique, patient-relevant tool for the development and optimization of DC-directed T1D therapies.
- 16 April 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (5) , 879-886
The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease that is caused, in part, by T cell–mediated destruction of insulin-producing β-cells. High risk for disease, in those with genetic susceptibility, is predicted by the presence of two or more autoantibodies against insulin, the 65-kDa form of glutamic acid decarboxylase (GAD65), insulinoma-associated protein 2 (IA-2), and zinc transporter 8 (ZnT8). Despite this knowledge, we still do not know what leads to the breakdown of tolerance to these autoantigens, and we have an incomplete understanding of T1D etiology and pathophysiology. Several new autoantibodies have recently been discovered using innovative technologies, but neither their potential utility in monitoring disease development and treatment nor their role in the pathophysiology and etiology of T1D has been explored. Moreover, neoantigen generation (through posttranslational modification, the formation of hybrid peptides containing two distinct regions of an antigen or antigens, alternative open reading frame usage, and translation of RNA splicing variants) has been reported, and autoreactive T cells that target these neoantigens have been identified. Collectively, these new studies provide a conceptual framework to understand the breakdown of self-tolerance, if such modifications occur in a tissue- or disease-specific context. A recent workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases brought together investigators who are using new methods and technologies to identify autoantigens and characterize immune responses toward these proteins. Researchers with diverse expertise shared ideas and identified resources to accelerate antigen discovery and the detection of autoimmune responses in T1D. The application of this knowledge will direct strategies for the identification of improved biomarkers for disease progression and treatment response monitoring and, ultimately, will form the foundation for novel antigen-specific therapeutics. This Perspective highlights the key issues that were addressed at the workshop and identifies areas for future investigation.
- 16 April 2019
- Published by American Diabetes Association in Diabetes
- Vol. 68 (5) , 879-886
The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease that is caused, in part, by T cell–mediated destruction of insulin-producing β-cells. High risk for disease, in those with genetic susceptibility, is predicted by the presence of two or more autoantibodies against insulin, the 65-kDa form of glutamic acid decarboxylase (GAD65), insulinoma-associated protein 2 (IA-2), and zinc transporter 8 (ZnT8). Despite this knowledge, we still do not know what leads to the breakdown of tolerance to these autoantigens, and we have an incomplete understanding of T1D etiology and pathophysiology. Several new autoantibodies have recently been discovered using innovative technologies, but neither their potential utility in monitoring disease development and treatment nor their role in the pathophysiology and etiology of T1D has been explored. Moreover, neoantigen generation (through posttranslational modification, the formation of hybrid peptides containing two distinct regions of an antigen or antigens, alternative open reading frame usage, and translation of RNA splicing variants) has been reported, and autoreactive T cells that target these neoantigens have been identified. Collectively, these new studies provide a conceptual framework to understand the breakdown of self-tolerance, if such modifications occur in a tissue- or disease-specific context. A recent workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases brought together investigators who are using new methods and technologies to identify autoantigens and characterize immune responses toward these proteins. Researchers with diverse expertise shared ideas and identified resources to accelerate antigen discovery and the detection of autoimmune responses in T1D. The application of this knowledge will direct strategies for the identification of improved biomarkers for disease progression and treatment response monitoring and, ultimately, will form the foundation for novel antigen-specific therapeutics. This Perspective highlights the key issues that were addressed at the workshop and identifies areas for future investigation.
- Open Access
- 15 May 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (10) , 3353-3363
HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression
Type 1 diabetes (T1D) is characterized by T cell–mediated destruction of the insulin-producing β cells of the pancreatic islets. Among the loci associated with T1D risk, those most predisposing are found in the MHC region. HLA-B*39:06 is the most predisposing class I MHC allele and is associated with an early age of onset. To establish an NOD mouse model for the study of HLA-B*39:06, we expressed it in the absence of murine class I MHC. HLA-B*39:06 was able to mediate the development of CD8 T cells, support lymphocytic infiltration of the islets, and confer T1D susceptibility. Because reduced thymic insulin expression is associated with impaired immunological tolerance to insulin and increased T1D risk in patients, we incorporated this in our model as well, finding that HLA-B*39:06–transgenic NOD mice with reduced thymic insulin expression have an earlier age of disease onset and a higher overall prevalence as compared with littermates with typical thymic insulin expression. This was despite virtually indistinguishable blood insulin levels, T cell subset percentages, and TCR Vβ family usage, confirming that reduced thymic insulin expression does not impact T cell development on a global scale. Rather, it will facilitate the thymic escape of insulin-reactive HLA-B*39:06–restricted T cells, which participate in β cell destruction. We also found that in mice expressing either HLA-B*39:06 or HLA-A*02:01 in the absence of murine class I MHC, HLA transgene identity alters TCR Vβ usage by CD8 T cells, demonstrating that some TCR Vβ families have a preference for particular class I MHC alleles.
- 15 May 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 200 (10) , 3353-3363
Open AccessHLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression
Type 1 diabetes (T1D) is characterized by T cell–mediated destruction of the insulin-producing β cells of the pancreatic islets. Among the loci associated with T1D risk, those most predisposing are found in the MHC region. HLA-B*39:06 is the most predisposing class I MHC allele and is associated with an early age of onset. To establish an NOD mouse model for the study of HLA-B*39:06, we expressed it in the absence of murine class I MHC. HLA-B*39:06 was able to mediate the development of CD8 T cells, support lymphocytic infiltration of the islets, and confer T1D susceptibility. Because reduced thymic insulin expression is associated with impaired immunological tolerance to insulin and increased T1D risk in patients, we incorporated this in our model as well, finding that HLA-B*39:06–transgenic NOD mice with reduced thymic insulin expression have an earlier age of disease onset and a higher overall prevalence as compared with littermates with typical thymic insulin expression. This was despite virtually indistinguishable blood insulin levels, T cell subset percentages, and TCR Vβ family usage, confirming that reduced thymic insulin expression does not impact T cell development on a global scale. Rather, it will facilitate the thymic escape of insulin-reactive HLA-B*39:06–restricted T cells, which participate in β cell destruction. We also found that in mice expressing either HLA-B*39:06 or HLA-A*02:01 in the absence of murine class I MHC, HLA transgene identity alters TCR Vβ usage by CD8 T cells, demonstrating that some TCR Vβ families have a preference for particular class I MHC alleles.
- Open Access
HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression 1
Type 1 diabetes (T1D) is characterized by T cell-mediated destruction of the insulin-producing βcells of the pancreatic islets. Among the loci associated with T1D risk, those most predisposing are found in the MHC region. HLA-B*39:06 is the most predisposing class I MHC allele and is associated with an early age of onset. To establish an NOD mouse model for the study of HLA-B*39:06, we expressed it in the absence of murine class I MHC. HLA-B*39:06 was able to mediate the development of CD8 T cells, support lymphocytic infiltration of the islets, and confer T1D susceptibility. Because reduced thymic insulin expression is associated with increased T1D risk in patients, we incorporated this in our model as well, finding that HLA-B*39:06-transgenic NOD mice with reduced thymic insulin expression have an earlier age of disease onset and a higher overall prevalence as compared to littermates with typical thymic insulin expression. This was despite virtually indistinguishable blood insulin levels, T cell subset percentages, and TCR Vβ family usage, indicating that reduced thymic insulin expression does not impact T cell development on a global scale. Rather, we propose that it allows the thymic escape of insulin-reactive HLA-B*39:06-restricted T cells which participate in β cell destruction. We also found that in mice expressing either HLA-B*39:06 or HLA-A*02:01 in the absence of murine class I MHC, HLA transgene identity alters TCR Vβ usage, which may contribute to varying diabetogenic CD8 T cell repertoires in the presence of different HLA class I alleles.
Open AccessHLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression 1
Type 1 diabetes (T1D) is characterized by T cell-mediated destruction of the insulin-producing βcells of the pancreatic islets. Among the loci associated with T1D risk, those most predisposing are found in the MHC region. HLA-B*39:06 is the most predisposing class I MHC allele and is associated with an early age of onset. To establish an NOD mouse model for the study of HLA-B*39:06, we expressed it in the absence of murine class I MHC. HLA-B*39:06 was able to mediate the development of CD8 T cells, support lymphocytic infiltration of the islets, and confer T1D susceptibility. Because reduced thymic insulin expression is associated with increased T1D risk in patients, we incorporated this in our model as well, finding that HLA-B*39:06-transgenic NOD mice with reduced thymic insulin expression have an earlier age of disease onset and a higher overall prevalence as compared to littermates with typical thymic insulin expression. This was despite virtually indistinguishable blood insulin levels, T cell subset percentages, and TCR Vβ family usage, indicating that reduced thymic insulin expression does not impact T cell development on a global scale. Rather, we propose that it allows the thymic escape of insulin-reactive HLA-B*39:06-restricted T cells which participate in β cell destruction. We also found that in mice expressing either HLA-B*39:06 or HLA-A*02:01 in the absence of murine class I MHC, HLA transgene identity alters TCR Vβ usage, which may contribute to varying diabetogenic CD8 T cell repertoires in the presence of different HLA class I alleles.